Skip to main content

Vulvovaginal Atrophy

3
Pipeline Programs
5
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Peptonic Medical
Peptonic MedicalSweden - Stockholm
1 program
1
Oxytocin 400 IU vaginal gelPhase 21 trial
Active Trials
NCT04629885Completed202Est. May 2017
Daré Bioscience
Daré BioscienceCA - San Diego
2 programs
1
1
IVR Dose 1Phase 1/21 trial
IVR Dose 1Phase 11 trial
Active Trials
NCT05418426Completed34Est. Jan 2022
NCT05367973Completed21Est. Mar 2023
Madorra
MadorraOR - Portland
1 program
Non-hormonal vaginal device therapyN/A1 trial
Active Trials
NCT04887701Completed25Est. Aug 2022
Shionogi
ShionogiJapan - Osaka
1 program
Women's Satisfaction and Adherence to Vulvovaginal Atrophy TreatmentsN/A1 trial
Active Trials
NCT04607707Completed831Est. Apr 2021
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
Estradiol 10 MCG Vaginal Tablet [VAGIFEM]PHASE_31 trial
Active Trials
NCT04232813Completed120Est. Nov 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskEstradiol 10 MCG Vaginal Tablet [VAGIFEM]
Peptonic MedicalOxytocin 400 IU vaginal gel
Daré BioscienceIVR Dose 1
Daré BioscienceIVR Dose 1
MadorraNon-hormonal vaginal device therapy
ShionogiWomen's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments

Clinical Trials (6)

Total enrollment: 1,233 patients across 6 trials

NCT04232813Novo NordiskEstradiol 10 MCG Vaginal Tablet [VAGIFEM]

Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream

Start: Jan 2020Est. completion: Nov 2020120 patients
Phase 3Completed
NCT04629885Peptonic MedicalOxytocin 400 IU vaginal gel

Study to Evaluate Efficacy of Vagitocin in Postmenopausal Women With Vulvovaginal Atrophy Symptoms

Start: May 2016Est. completion: May 2017202 patients
Phase 2Completed
NCT05367973Daré BioscienceIVR Dose 1

Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women

Start: Apr 2022Est. completion: Mar 202321 patients
Phase 1/2Completed
NCT05418426Daré BioscienceIVR Dose 1

A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women

Start: Aug 2020Est. completion: Jan 202234 patients
Phase 1Completed
NCT04887701MadorraNon-hormonal vaginal device therapy

Non-hormonal Medical Device for Treatment of Vulvovaginal Atrophy (VVA) in Post-Menopausal Women

Start: Jul 2021Est. completion: Aug 202225 patients
N/ACompleted
NCT04607707ShionogiWomen's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments

Women's Satisfaction and Adherence to Vulvovaginal Atrophy Treatments

Start: Jul 2020Est. completion: Apr 2021831 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.